BMJ Study Notes Potential Twofold Increase In GI Bleed Risk Lending Support To Xarelto Lawsuit Plaintiffs

February 22, 2016 – – BloodThinnerHelp.com reports on results of multiple studies which appear to link the use of blood thinning drug Xarelto to an increased risk of dangerous and sudden bleeding episodes in patients, such as spontaneous vitreous hemorrhages, (or eye bleeds), and internal gastrointestinal bleeds, among others. These results bring concern to the general public but help to lend support to current Xarelto bleeding lawsuit plaintiffs.

Xarelto bleeding lawsuits which were filed in federal courts across the nation have been consolidated by the U.S. Judicial Panel on multidistrict litigation to form MDL No. 2592. All share common allegations and have been filed against Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson). At this time, cases consolidated in the MDL number over 2,800, and these cases are joined by another group of over 550 filings in Philadelphia, Pennsylvania, which have been consolidated by the Court of Common Pleas to form a mass tort group.

JAMA Ophthalmology published a study on June 25th of 2015 which appeared to show a link between consumer use of rivaroxaban (Xarelto’s generic form) and an increased risk of the development of sudden hemorrhaging episodes within the eyes. Doctors who conducted the research additionally discovered that “the risk of hemorrhage may be particularly elevated during the transition period when patients are switched from baseline anticoagulant to rivaroxaban therapy and are taking both anticoagulants simultaneously.” This is concerning information for patients who were using traditional blood thinners before switching to use Xarelto.

Xarelto has also been the recipient of two black box warnings from the U.S. Food and Drug Administration (FDA). This is the most severe warning a product is able to be given before it is completely pulled from the market, yet, these warnings and studies are not alone.

An additional study linking certain possible health risks to Xarelto was published in BMJ’s (British Medical Journal) April 2015 issue, and the results of this study showed that Xarelto (rivaroxaban) use could potentially double a patient’s risk of suffering gastrointestinal bleeds when compared with patients using warfarin (a traditional blood thinner). After finishing the study, researchers noted, “…we cannot rule out…a more than twofold higher risk of bleeding with rivaroxaban compared with warfarin.”

Attorney Joseph Osborne has seen the devastating and potentially fatal effects of serious bleeding episodes in patients, and understands them well. He is currently looking to help anyone who has suffered from serious health issues that they link to Xarelto use. He feels that these individuals are entitled to the important opportunity of exploring their legal rights in full. They may qualify for legal action or substantial compensation. To encourage these potential victims to pursue justice, Attorney Osborne is currently offering free legal consultations for qualifying individuals.

To request additional Xarelto bleeding lawsuit information, or to ask questions, please contact attorney Joseph Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008277